The Pharmacological Action of Kaempferol in Central Nervous System Diseases: A Review

被引:135
|
作者
Silva dos Santos, Jessica [1 ]
Goncalves Cirino, Joao Pedro [2 ]
de Oliveira Carvalho, Patricia [2 ]
Ortega, Manoela Marques [1 ]
机构
[1] Sao Francisco Univ USF, Post Grad Program Hlth Sci, Lab Cell & Mol Tumor Biol & Bioact Cpds, Braganca Paulista, SP, Brazil
[2] Sao Francisco Univ USF, Post Grad Program Hlth Sci, Lab Multidisciplinary Res, Braganca Paulista, SP, Brazil
关键词
flavonoids; kaempferol; Alzheimer; Parkinson; ischemia stroke; epilepsy; glioblastoma; FLAVONOID-GLYCOSIDES; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; MULTIDRUG-RESISTANCE; PHENOLIC GLYCOSIDES; COGNITIVE DECLINE; KAPPA-B; MECHANISMS; ANTIOXIDANT; BRAIN;
D O I
10.3389/fphar.2020.565700
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Kaempferol (KPF) is a flavonoid antioxidant found in fruits and vegetables. Many studies have described the beneficial effects of dietary KPF in reducing the risk of chronic diseases, especially cancer. Nevertheless, little is known about the cellular and molecular mechanisms underlying KPF actions in the central nervous system (CNS). Also, the relationship between KPF structural properties and their glycosylation and the biological benefits of these compounds is unclear. The aim of this study was to review studies published in the PubMed database during the last 10 years (2010-2020), considering only experimental articles that addressed the isolated cell effect of KPF (C15H10O6) and its derivatives in neurological diseases such as Alzheimer's disease, Parkinson, ischemia stroke, epilepsy, major depressive disorder, anxiety disorders, neuropathic pain, and glioblastoma. 27 publications were included in the present review, which presented recent advances in the effects of KPF on the nervous system. KPF has presented a multipotential neuroprotective action through the modulation of several proinflammatory signaling pathways such as the nuclear factor kappa B (NF-kB), p38 mitogen-activated protein kinases (p38MAPK), serine/threonine kinase (AKT), and beta-catenin cascade. In addition, there are different biological benefits and pharmacokinetic behaviors between KPF aglycone and its glycosides. The antioxidant nature of KPF was observed in all neurological diseases through MMP2, MMP3, and MMP9 metalloproteinase inhibition; reactive oxygen species generation inhibition; endogenous antioxidants modulation as superoxide dismutase and glutathione; formation and aggregation of beta-amyloid (beta-A) protein inhibition; and brain protective action through the modulation of brain-derived neurotrophic factor (BDNF), important for neural plasticity. In conclusion, we suggest that KPF and some glycosylated derivatives (KPF-3-O-rhamnoside, KPF-3-O-glucoside, KPF-7-O-rutinoside, and KPF-4 '-methyl ether) have a multipotential neuroprotective action in CNS diseases, and further studies may make the KPF effect mechanisms in those pathologies clearer. Future in vivo studies are needed to clarify the mechanism of KPF action in CNS diseases as well as the impact of glycosylation on KPF bioactivity.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Pharmacological effects of salidroside on central nervous system diseases
    Jin, Meihua
    Wang, Chun
    Xu, Yifeng
    Zhang, Zijing
    Wu, Xueyan
    Ye, Runfa
    Zhang, Qinggao
    Han, Donghe
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2022, 156
  • [2] The pharmacological action of deuterium oxide VIII Action on the central nervous system
    Herrmann, JB
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1939, 67 (03): : 265 - 275
  • [3] DISEASES OF CENTRAL NERVOUS-SYSTEM - PHARMACOLOGICAL BASIS OF TREATMENT
    GILBERT, JC
    [J]. BRITISH MEDICAL JOURNAL, 1975, 4 (5987): : 33 - 35
  • [4] A Review on Lactoferrin and Central Nervous System Diseases
    Li, Yu-Qi
    Guo, Chuang
    [J]. CELLS, 2021, 10 (07)
  • [5] VIRUS DISEASES OF THE CENTRAL NERVOUS SYSTEM - A REVIEW
    GEAR, J
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1949, 12 (01): : 66 - 76
  • [6] Ginsenosides in central nervous system diseases: Pharmacological actions, mechanisms, and therapeutics
    Lu, Jing
    Wang, Xian
    Wu, Anxin
    Cao, Yi
    Dai, Xiaolin
    Liang, Youdan
    Li, Xiaofang
    [J]. PHYTOTHERAPY RESEARCH, 2022, 36 (04) : 1523 - 1544
  • [7] Pharmacological activities, mechanisms of action, and safety of salidroside in the central nervous system
    Zhong, Zhifeng
    Han, Jing
    Zhang, Jizhou
    Xiao, Qing
    Hu, Juan
    Chen, Lidian
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1479 - 1489
  • [8] A review for the pharmacological effect of lycopene in central nervous system disorders
    Chen, Dongjian
    Huang, Chao
    Chen, Zhuo
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2019, 111 : 791 - 801
  • [9] PHARMACOLOGICAL PROPERTIES OF BENZAZOLES .2. SITES OF ACTION IN THE CENTRAL NERVOUS SYSTEM
    FUNDERBURK, WH
    KING, EE
    DOMINO, EF
    UNNA, KR
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1953, 107 (03): : 356 - 367
  • [10] Central nervous system diseases
    Cortelli, Pietro
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 7 - 7